कंपनी का अवलोकन
Artelo Biosciences, Inc. operates as a clinical stage biopharmaceutical entity focused on the development and commercialization of therapeutics that specifically target lipid-signaling pathways within the United States market. The company's strategic portfolio includes the lead product candidate ART27.13, which functions as a synthetic dual cannabinoid G protein-coupled receptor agonist, representing the core of its pipeline for potential therapeutic applications. This biotechnology firm functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, positioning it among entities dedicated to advancing medical treatments through scientific innovation. In terms of scale, the company holds a market capitalization of $5.32M and employs a workforce of 7 individuals, while its trailing twelve-month revenue figures are unavailable for public reporting. These valuation metrics indicate that Artelo Biosciences, Inc. operates as a micro-cap entity with limited financial resources, a status typical for early-stage biotech firms that prioritize research and development expenditures over immediate profitability. The absence of reported revenue data further underscores the company's developmental stage, where capital allocation is directed toward clinical trials and asset advancement rather than widespread commercial sales.
वित्तीय स्वास्थ्य
The financial statements for Artelo Biosciences, Inc. reveal a net income loss of $-12,879,000 over the trailing twelve-month period, while both gross margin and operating margin are recorded at 0.0%, indicating that the company has not yet achieved commercial profitability. The gap between the reported revenue, which is unavailable, and the significant net income loss highlights a cost structure dominated by high burn rates associated with clinical-stage research and development activities. Free cash flow stands at $-4,168,625, reflecting a substantial cash outflow that necessitates continuous external financing to sustain operations and fund ongoing scientific endeavors. The company maintains a cash balance of $600,000 against total debt obligations of $678,000, resulting in a net cash position that is slightly negative, which implies a reliance on equity markets or other capital instruments to meet short-term liabilities. Profit margins are also listed at 0.0%, consistent with the gross and operating margins, signaling that the company is currently in an investment phase where expenses vastly outweigh any potential revenue streams. The return on equity is recorded at -1625.1%, and the return on assets is -190.1%, metrics that indicate the company is currently destroying shareholder value as it attempts to build a pipeline without established revenue generation. Furthermore, the current ratio is 0.17, a figure that suggests the company possesses significantly fewer current assets than current liabilities, highlighting a precarious short-term liquidity position that requires careful management of cash reserves.
मूल्यांकन आकलन
Valuation metrics for Artelo Biosciences, Inc. present a complex picture, with a trailing twelve-month P/E ratio listed as N/A due to the absence of positive earnings, while the forward P/E is calculated at -7.40, indicating negative expected earnings in the near term. The price-to-book ratio stands at -3.44, a negative figure that suggests the company's market valuation is detached from its book value, a common occurrence for biotechnology firms with significant intangible assets or pending clinical data that is not fully reflected on the balance sheet. Alternative valuation measures such as the price-to-sales ratio and EV/EBITDA are also unavailable, reflecting the lack of sales data and negative earnings that prevent the use of these traditional multiples for comparison with peers. The stock has exhibited significant volatility, trading between a 52-week high of $85.80 and a 52-week low of $2.96, demonstrating a wide trading range that captures substantial price swings over the past year. Given the 52-week low of $2.96 and the high of $85.80, the current price point sits in a context of extreme variability, though the exact current price is not provided to calculate a precise percentage, the range itself highlights the speculative nature of the security. The beta value is 0.41, which indicates that the stock price tends to be less volatile than the broader market, moving with lower magnitude relative to market-wide fluctuations despite the dramatic 52-week range observed.
Growth & Income
Growth metrics for Artelo Biosciences, Inc. show revenue growth year-over-year as N/A, as well as earnings growth year-over-year as N/A, due to the company's status as a pre-revenue entity with no historical sales data for comparison. Since revenue growth and earnings growth cannot be quantified, it is impossible to determine whether earnings are growing faster or slower than revenue, as both figures are currently undefined in the public domain. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available capital and earnings are reinvested back into the business to fund research, development, and clinical trials rather than being distributed to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies, as they must conserve cash to advance their product candidates through regulatory hurdles and into market approval. The overall growth and income profile of Artelo Biosciences, Inc. is characterized by an absence of current income generation and undefined growth rates, relying entirely on future potential clinical success to realize value for investors in the Healthcare sector.